FREE DELIVERY ON ALL ORDERS OVER £29*

*Conditions apply - details
Shop by Category
Please enable cookies to use this site. Why?

Milpro for Cats

Milpro for Cats is for the treatment of mixed infections by immature and adult cestodes (tapeworm) and adult nematodes (roundworms) of the following species:
Cestodes, Dipylidium caninum, Taenia spp, Nematodes, Ancylostoma tubaeforme, Toxocara cati

The product can also be used in the prevention of heartworm disease (Dirofilaria immitis), if concomitant treatment against cestodes is indicated.

Milpro Worming Tablets for Cats

Milpro Worming Tablets for Cats

£4.72

Milpro Worming Tablets for Cats are for the treatment of mixed infections by immature and adult cestodes (tapeworms) and adult nematodes (roundworms). Each tablet contains as active...[More info]

£4.72
Milpro Worming Tablets for Cats (4 Pack)

Milpro Worming Tablets for Cats (4 Pack)

£17.65

Milpro Worming Tablets for Cats are for the treatment of mixed infections by immature and adult cestodes (tapeworms) and adult nematodes (roundworms). Each tablet contains as active...[More info]

£17.65
Milpro Worming Tablets for Small Cats and Kittens

Milpro Worming Tablets for Small Cats and Kittens

£2.27

Milpro Worming Tablets for Small Cats and Kittens are for the treatment of mixed infections by immature and adult cestodes (tapeworms) and adult nematodes (roundworms). Each tablet contains...[More info]

£2.27
Target species
Cats
 
Indications for use
In cats: treatment of mixed infections by immature and adult cestodes (tapeworms) and adult nematodes (roundworms) of the following species:
Cestodes:
Dipylidium caninum,
Taenia spp.,
Nematodes:
Ancylostoma tubaeforme,
Toxocara cati
Prevention of heartworm disease (Dirofilaria immitis), if concomitant treatment against cestodes is indicated.
 
Contra-indications
Milpro for small cats and kittens: Do not use in kittens of less than 6 weeks of age and/or weighing less than 0.5 kg.
Milpro for cats: Do not use in cats weighing less than 2kg
Do not use in cases of hypersensitivity to the active substances or to any of the excipients.
 
Special warnings for each target species
It is recommended to treat all the animals living in the same household concomitantly.
In order to develop an effective worm control programme local epidemiological information and the living conditions of the cat should be taken into account and therefore it is recommended to seek professional advice.
Parasite resistance to any particular class of anthelmintic may develop following frequent, repeated use of an anthelmintic of that class.
When D. caninum infection is present, concomitant treatment against intermediate hosts, such as fleas and lice, should be considered to prevent re-infection.
 
Special precautions for use
Special precautions for use in animals
No studies have been performed with severely debilitated cats or individuals with seriously compromised kidney or liver function. The product is not recommended for such animals or only according to a benefit/risk assessment by the responsible veterinarian.
Studies have shown that treatment of dogs with a high number of circulating microfilariae can sometimes lead to the appearance of hypersensitivity reactions, such as pale mucous membranes, vomiting, trembling, laboured breathing or excessive salivation. These reactions are associated with the release of proteins from dead or dying microfilariae and are not a direct toxic effect of the product. The use in dogs suffering from microfilaremia is thus not recommended. In the absence of data on cats with microfilaraemia, its use should be according to a benefit risk assessment by the attending veterinarian.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
Wash hands after use.
In the event of accidental ingestion of the tablets, particularly by a child, seek medical advice immediately and show the package leaflet or the label to the doctor.
 
Adverse reactions
In very rare occasions, especially in young cats, systemic signs (such as lethargy), neurological signs (such as ataxia and muscle tremors) and/or gastrointestinal signs (such as emesis and diarrhoea) may be observed after administration of the veterinary medicinal product.
 
Use during pregnancy, lactation or lay
In a study, this combination of active substances was demonstrated to be well tolerated in breeding bitches, including during pregnancy and lactation. As a specific study with this product has not been performed, use during pregnancy and lactation only according to a benefit/risk assessment by the responsible veterinarian
 
Interactions
The concurrent use of the combination praziquantel/milbemycin oxime with selamectin is well tolerated. No interactions were observed when the recommended dose of the macrocyclic lactone selamectin was administered during treatment with the combination at the recommended dose. In the absence of further studies, caution should be taken in the case of concurrent use of the product and other macrocyclic lactones. Also no such studies have been performed with reproducing animals
 
Amounts to be administered and administration route
Oral use.
As per good veterinary practice, animals should be weighed to ensure accurate dosing.
Minimum recommended dose rate: 2 mg of milbemycin oxime and 5 mg of praziquantel per kg are given orally as a single dose.
The product should be administered with or after some food.
The product is a small size tablet.
To aid with administration, the product has been coated with a meat flavour.
The tablets can be divided into halves.
Depending on the bodyweight of the cat, the practical dosing is as follows:
 
 WeightTablets
Milpro 4mg/10mg for Small Cats and Kittens 0.5-1kg
1-2kg
1/2 tablet
1 tablet
Milpro 16mg/40mg for Cats 2-4kg
4-8kg
8-12kg
1/2 tablet
1 tablet
1 1/2 tablets

In cases when heartworm disease prevention is used and at the same time treatment against tapeworm is required, the product can replace the monovalent product for the monthly prevention of heartworm disease.
 
Overdose
In a study conducted with the product administered at 1X, 3X and 5X the therapeutic dose, and for a duration which exceed the therapeutic indication, i.e. 3 times at 15 day-intervals, signs uncommonly reported at the recommended dose (see section 4.6) have been observed at 5-fold the therapeutic dose after the second and third treatments. These signs disappeared spontaneously within a day.
 
Withdrawal periods
Not applicable